Stockscreener 앱 받기
0.93%
Pfizer Inc 주식(PFE)의 최신 뉴스
Pfizer’s High-Yield Dividend Attracts Investor Scrutiny - AD HOC NEWS
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom - TechStock²
Pfizer Inc Is On Sale: Viral Hype Or Big Pharma Value Trap? - AD HOC NEWS
Key facts: Pfizer's stock yields 6.7%; CEO criticizes vaccine plan - TradingView — Track All Markets
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land - TechStock²
Could Pfizer Inc.'s (NYSE:PFE) Weak Financials Mean That The Market Could Correct Its Share Price? - Yahoo Finance
Key facts: Pfizer's stock yields 6.7%; explores FDA program; Chantix study results - TradingView — Track All Markets
Lobbying Update: $60,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer: Rebound Has Just Started (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) CEO Isn't Ready For A Fight With RFK Jr., Says Jim Cramer - Finviz
Pfizer (PFE) CEO Isn’t Ready For A Fight With RFK Jr., Says Jim Cramer - Yahoo Finance
GWN Securities Inc. Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends - GlobeNewswire Inc.
Pfizer Stock Just Flipped the Script: Crash, Comeback, or Total Cap? - AD HOC NEWS
Pfizer’s Abrocitinib Atopic Dermatitis Study Nears Data Milestone: What Investors Should Watch - TipRanks
Campbell & CO Investment Adviser LLC Has $3.38 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Has The Market Overlooked Pfizer (PFE) After The Post‑Pandemic Reset? - simplywall.st
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook - TechStock²
Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30 - Finviz
Pfizer Advances Prazosin Manufacturing Shift With New Bioequivalence Study - TipRanks
Pfizer’s TOFAst Real-World Study in Ulcerative Colitis: What Investors Should Watch - TipRanks
News | Expect more big loan pools in 2026; Loan refinances San Diego Pfizer campus; Critical refinancing tests loom - CoStar
Pfizer Stock Under Pressure: Is This Pharma Giant a Deep Value Play or a Value Trap? - AD HOC NEWS
Pfizer: The Most Intriguing Value Play Of 2026 (NYSE:PFE) - Seeking Alpha
Pfizer’s Strategic Pivot: Obesity Drug Push and Regulatory Tailwinds - AD HOC NEWS
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Trading 1.6% HigherWhat's Next? - MarketBeat
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Pfizer Inc - Reuters
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus - TechStock²
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings - TechStock²
Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant - TipRanks
Pfizer’s Strategic Pivot Meets Skeptical Market Response - AD HOC NEWS
Novo’s CEO Is Ready to Go ‘Very Big’ in Hunt for Obesity Deals - Bloomberg.com
Bull Run: Why Pfizer Inc stock remains on watchlistsOil Prices & Risk Managed Investment Entry Signals - moha.gov.vn
Should Pfizer’s Oncology Win And Obesity Push Require Action From Pfizer (PFE) Investors? - simplywall.st
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy - Yahoo Finance
Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher - Yahoo Finance
Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option - TipRanks
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra” - TechStock²
Inside Pfizer's Oncology Performance Ahead of Q4 Results - The Globe and Mail
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff - BioSpace
TD Private Client Wealth LLC Acquires 80,571 Shares of Pfizer Inc. $PFE - MarketBeat
Tema Etfs LLC Purchases Shares of 93,166 Pfizer Inc. $PFE - MarketBeat
Antidepressant Market Is Booming So Rapidly | Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, AstraZeneca - openPR.com
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy (NYSE:PFE) - Seeking Alpha
Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company - Yahoo Finance
Bogart Wealth LLC Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition - Stocktwits
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow (NYSE:PFE) 2026-01-13 - Seeking Alpha
(01/13/26) Top Picks 2026: Pfizer Inc. (PFE) - moneyshow.com
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra” - TechStock²
Stock Recap: Can Pfizer Inc lead its sector in growthQuarterly Market Review & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra - Yahoo! Finance Canada
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
UBS Likes Pfizer's MTSR Obesity Deal but Stays Neutral on PFE - Finviz
UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE - Yahoo Finance
Pfizer Talking to Trump Administration About Priority Vouchers - Bloomberg.com
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution - PharmExec.com
Pfizer CEO sees growth in international segments, modest growth for US in next few years - marketscreener.com
Pfizer CEO says expects to launch next-gen obesity assets acquired through Metsera buyout in 2028: JPM Conf - marketscreener.com
Update Recap: Is Pfizer Inc currently under institutional pressureJuly 2025 Opening Moves & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial - Benzinga
Pfizer Advances New Lung Cancer Combo in Global Phase 2/3 Trial: What Investors Should Watch - TipRanks
Stock Watch: What’s Pfizer Hiding Behind COVID Product Decline And Patent Losses? - Citeline News & Insights
3.01%
1.85%
자본화:
|
볼륨(24시간):